

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted - Prior orchiectomy or medical castration; participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) - fully active, able to carry on all pre-disease performance without restriction or unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- active autoimmune disease in the 12 months that requires systemic immunosuppressive medications (example, chronic corticosteroids, methotrexate, or tacrolimus) - any of the following within past 6 months: myocardial infarction, severe or unstable angina, significant ventricular arrhythmias, congestive heart failure, transient ischemic attack (TIA), or Cerebrovascular accident (CVA, stroke) - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:

Drug: JNJ-78278343, Drug: JNJ-87189401

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), mCRPC, Prostate cancer

More Information

Description: The purpose of this study is to assess whether JNJ-87189401 given in combination with pasritamig (JNJ-78278343) to men with metastatic castration-resistant prostate cancer (also known as mCRPC) can cause side effects, and to find doses for the two drugs when given in combination. Side effects are unexpected or unwanted reactions from receiving the study drugs. Additionally, the study will look at how long JNJ-87189401 and pasritamig stay in the body, how they act on the body, and how the body responds to them.

Study Contact: Nicholas Zorko - zorko004@umn.edu

Principal Investigator: Nicholas Zorko

Phase: PHASE1

IRB Number: STUDY00027319

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.